Marksans Pharma Intrinsic Value
Marksans Pharma intrinsic value. Marksans Pharma (MARKSANS) median intrinsic value is ₹598.10 from 10 valuation models (range ₹90–₹748), vs current price ₹299.05 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse MARKSANS financial statements for revenue, profit, balance sheet and cash flow data.
MARKSANS Valuation Methods Summary — DCF, Graham Number & P/E
Marksans Pharma intrinsic value across 10 models vs current price ₹299.05 — upside/downside and value range per method. Analyse Marksans Pharma ownership structure to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹274.56 | ₹219.65 - ₹329.47 | -8.2% | EPS: ₹12.48, Sector P/E: 22x |
| Book Value Method | asset | ₹747.62 | ₹672.86 - ₹822.38 | +150.0% | Book Value/Share: ₹678.44, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹598.10 | ₹538.29 - ₹657.91 | +100.0% | Revenue/Share: ₹851.56, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹598.10 | ₹538.29 - ₹657.91 | +100.0% | EBITDA: ₹928.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹747.62 | ₹598.10 - ₹897.14 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹89.72 | ₹80.75 - ₹98.69 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹192.82 | ₹173.54 - ₹212.10 | -35.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹598.10 | ₹538.29 - ₹657.91 | +100.0% | ROE: 18.9%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹436.47 | ₹392.82 - ₹480.12 | +46.0% | EPS: ₹12.48, BVPS: ₹678.44 |
| Dividend Yield Method | dividend | ₹89.72 | ₹80.75 - ₹98.69 | -70.0% | DPS: ₹0.90, Target Yield: 2.5% |
MARKSANS Intrinsic Value vs Market Price — All Valuation Models
Marksans Pharma fair value range ₹90–₹748 vs current market price ₹299.05 across 10 valuation models. For current market price and key ratios, visit Marksans Pharma stock price NSE.
MARKSANS Intrinsic Value Analysis — Undervalued or Overvalued?
Marksans Pharma median intrinsic value ₹598.10, current price ₹299.05 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of MARKSANS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Marksans Pharma (MARKSANS) is ₹598.10 (median value). With the current market price of ₹299.05, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹89.72 to ₹747.62, indicating ₹89.72 - ₹747.62.
Is MARKSANS undervalued or overvalued?
Based on our multi-method analysis, Marksans Pharma (MARKSANS) appears to be trading below calculated value by approximately 100.0%.
MARKSANS Financial Health — Key Ratios vs Industry Benchmarks
Marksans Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 18.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.99x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MARKSANS Cash Flow Quality — Operating & Free Cash Flow
Marksans Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹458 Cr | ₹334 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹207 Cr | ₹183 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹230 Cr | ₹160 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹237 Cr | ₹108 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹99 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |